Ashling Wahner

Key Takeaways Accelerated approval covers HR-positive/HER2-negative advanced disease with acquired ESR1 mutation on prior aromatase inhibitor plus CDK4/6 inhibition, requiring identification by an FDA-approved companion diagnostic test. Clinical evidence derives from switching to oral camizestrant plus continued CDK4/6 inhibition versus maintaining aromatase inhibitor plus CDK4/6 inhibitor, demonstrating median PFS improvement (16.0 vs 9.2 months). The regimen positions camizestrant as an ESR1-resistance–directed endocrine backbone while preserving CDK4/6 blockade, aligning with a targeted approach to endocrine escape in metastatic disease. SHOW MORE

INCB161734 in KRAS G12D–Mutated Pancreatic Cancer: Key Highlights

Key Takeaways False positives frequently arise from sensitivity–specificity tradeoffs, and patients experience them as acute “cancer scares,” despite population-level acceptance of downstream benign findings. Psychological sequelae may persist months to years, driving hypervigilance and distress during surveillance intervals, particularly in higher-risk individuals with familial or genetic predisposition. Inadequate pretest counseling and post-result communication can degrade trust and reduce future screening adherence, whereas expectation-setting improves tolerance of diagnostic uncertainty. Downstream consequences include additional imaging, labs, specialty visits, and biopsies with procedure-related risks, time away from work, out-of-pocket costs, and inefficient resource allocation. Risk-stratifying diagnostics such as IsoPSA and Cx Bladder Triage aim to reduce unnecessary interventions by better discriminating clinically significant cancer from benign etiologies. SHOW MORE

Key Takeaways BRUIN CLL-313 was a randomized, open-label, active-controlled study in previously untreated CLL/SLL patients without known del(17p). A total of 282 participants were enrolled and randomized 1:1 to pirtobrutinib or bendamustine combined with a rituximab product. Pirtobrutinib was administered continuously until disease progression, while the comparator arm received bendamustine-rituximab for six cycles. SHOW MORE The FDA has approved pirtobrutinib for the treatment of adult patients with previously untreated CLL or SLL harboring no known 17p deletion.

Key Takeaways Docetaxel ± ramucirumab remains the post–PD-(L)1 standard, with real-world and contemporary controls suggesting median OS ~10–11 months, but patient selection is constrained by bleeding/thrombotic risks. Multiple phase 3 efforts have disappointed, including ramucirumab+pembrolizumab in Pragmatica-Lung and atezolizumab+cabozantinib in CONTACT-01, underscoring limits of PD-(L)1 recycling and add-on TKIs. Bispecific and cytokine-based immunomodulation is gaining traction; PD-1/IL-2 bispecific IBI363 showed encouraging phase 1 activity in immunotherapy-pretreated squamous NSCLC (median PFS 10.1 months; OS 18.2 months). PRESERVE-003 stage 1 squamous subset (n=87) suggested improved OS with gotistobart vs docetaxel (18.5 vs 10.0 months; HR 0.56; nominal P=.0295) with comparable grade ≥3 TRAEs. CTLA-4–related irAEs demand anticipatory management, rapid escalation for colitis/endocrinopathies, routine lab monitoring, patient safety cards, and stronger academic–community communication pathways. SHOW MORE Lung cancer experts discuss emerging strategies after immunotherapy in advanced squamous NSCLC, including updated PRESERVE-003 data from WCLC 2026.

Novel NAMPT inhibitors may circumvent the limited tolerability of previously studied agents and improve treatment outcomes in AML and MDS.

The FDA has approved nogapendekin alfa inbakicept-pmln (Anktiva) in combination with BCG for the treatment of adult patients with BCG-unresponsive non–muscle-invasive bladder cancer (NMIBC) with high-grade papillary-only tumors.

With multiple ADCs now available for use in gynecologic cancers, treatment decision-making incorporates biomarker nuances and raises sequencing questions.

Moh'd Khushman, MD, discusses INCA33890's mechanism of action, phase 1 safety and efficacy data, and the design of NEXERA-303 in MSS colorectal cancer.